A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome (CIS-ON)

A Prospective, Open Label, Multi-centre Study Exploring the Use of Subcutaneous (sc) 44 Microgram Interferon (IFN) Beta - 1a (Rebif®) Once a Week (qw) in Subjects With Clinically Isolated Syndrome (CIS)

The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the conversion to Clinically Definite Multiple Sclerosis (CDMS) - as defined by the occurrence of a second exacerbation - over 96 weeks in subjects that present with Clinically Isolated Syndrome (CIS) accompanied by an abnormal magnetic resonance imaging (MRI). The secondary objectives are to:

• Assess the effectiveness of sc IFN beta - 1a (Rebif®) therapy in reducing the proportion of patients with CIS converting to CDMS
• Assess the safety of sc IFN beta - 1a (Rebif®) in the patients with CIS

Study Overview

• Status: Completed
• Conditions: Clinically Isolated Syndrome
• Intervention / Treatment: Drug: Rebif®; Other: No Treatment

• Study Type: Interventional
• Enrollment (Actual): 35
• Phase: Phase 3

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Windsor, Barrie, Hamilton, Mississauga, Ontario, Canada
      • Canadian Medical Information Office

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 65 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject must have experienced a first clinical episode suggestive of demyelinating disease
• Subject must present with an abnormal MRI displaying at least 3 T2 weighted hyperintense lesions typical of multiple sclerosis (MS)
• Subject must be greater than or equal to 18 years old
• Subject must have had onset of the clinical attack within the last 120 days
• Subject must give written informed consent
• Female subjects must be neither pregnant nor breast feeding, and must not be of child-bearing potential as defined by either:
• Being post-menopausal or surgically sterile
• Using hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study

Subjects electing treatment:

• Subject must be eligible for Interferon-beta 1-a therapy

Exclusion Criteria:

• Subject has evidence of other neurological diseases that could explain his/her symptomatology
• Subject is pregnant or in lactation
• Subject suffers from an intercurrent autoimmune disease
• Subject suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the procedures required by this study
• Subject has received immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporine, methotrexate, azathioprine, linomide, mitoxantrone, teriflunomide, natalizumab, laquinimod, campath), within 12 months of study day 1

Subjects electing treatment:

• Subject has inadequate liver function, defined by total bilirubin, aspartate transaminase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal values
• Subject has inadequate bone marrow reserve, defined as white blood cell count less than 0.5 times the lower limit of normal
• Subject has a known allergy to IFN or any of the excipients of the drug product

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Rebif®	Drug: Rebif®; 44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
Other: No Treatment	Other: No Treatment; No treatment for 96 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time in Month to Clinical Definite Multiple Sclerosis (CDMS) From Kaplan-Meier Estimates	CDMS was defined by the occurrence of a second exacerbation or relapse over 96 weeks in participants who presented with Clinically Isolated Syndrome (CIS) accompanied by an abnormal Magnetic Resonance Imaging (MRI) scan. Time was calculated from the date of the stabilization of the baseline CIS episode to the qualifying relapse for the CDMS.	Up to Week 96

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Converted to Clinical Definite Multiple Sclerosis (CDMS)	CDMS was defined as the occurrence of a second exacerbation over 96 weeks in participants who presented with CIS accompanied by an abnormal MRI scan.	Up to Week 96
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.	Up to Week 96

Collaborators and Investigators

• Sponsor: Merck KGaA, Darmstadt, Germany
• Collaborators: EMD Serono Canada Inc.
• Investigators: Study Director: Medical Director, EMD Serono Canada Inc.

Publications and helpful links

Helpful Links

• Full FDA approved prescribing information can be found here

Study record dates

Study Major Dates

• Study Start: October 1, 2005
• Primary Completion (Actual): November 1, 2008
• Study Completion (Actual): November 1, 2008

Study Registration Dates

• First Submitted: February 2, 2006
• First Submitted That Met QC Criteria: February 2, 2006
• First Posted (Estimate): February 6, 2006

Study Record Updates

• Last Update Posted (Estimate): December 27, 2013
• Last Update Submitted That Met QC Criteria: December 2, 2013
• Last Verified: December 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Syndrome
• Other Study ID Numbers: IMP 26222

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No